Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis

Multiple Myeloma (MM)

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Leuk Lymphoma

Park H, Robinson J, Flanagan C, Pawlyn C, Jackson G, Jones JR

doi: 10.1080/10428194.2025.2560085

Further Publications

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Am J Hematol

Filippatos C, Kanteli I, Pasipoularidou DG, Gavriatopoulou M, Tentolouris A, Malandrakis P, Sergentanis TN, Terpos E, Ntanasis-Stathopoulos I

doi: 10.1002/ajh.70201

Further Publications

Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials

Lancet Oncol

Zhu Y, Liu K, Rosen ST, Liu W, Zhu H

doi: 10.1016/S1470-2045(26)00086-0

Genitourinary Cancer

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

JAMA Oncol

Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L

doi: 10.1001/jamaoncol.2025.1891

Multiple Myeloma (MM)

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Ann Hematol

Benda M, Reimann P, Willenbacher W, Gunsilius E, Weisel K, Strassl I, Krauth MT, Knop S, Winder T, Steiner N

doi: 10.1007/s00277-026-07140-8

Lymphoma

Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis

Haematologica

Alhomoud M, Ibrahim R, Demetres M, Rejeski K, Scordo M, Shouval R, Tix T, Martinet J, Foley M, Gomez-Arteaga A, Shore T, Pagnini P, Aljurf M, Guzman ML, Formenti S, Yahalom J, Van Besien K, Imber BS, Chen Z, Yamshon S

doi: 10.3324/haematol.2025.287547

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

LeukemiaLymphomaCOVID-19

Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis

Leuk Lymphoma

Yu Y, Xiang Z, Hou X, Hu K, Zhang F

doi: 10.1080/10428194.2025.2572420

Lung, Respiratory and Thoracic CancerCOVID-19

Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer

Lung Cancer

Desai RK, Zhou EJ, Chan KKW

doi: 10.1016/j.lungcan.2025.108812

Related content

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials

Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review

Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Efficacy and safety of radiotherapy as a bridging strategy to CD19-targeted CAR-T therapy: systematic review and meta-analysis

Systematic review and network meta-analysis: evaluation of systemic therapies for platinum refractory or resistant small cell lung cancer